GlaxoSmithKline (GB:GSK) has released an update.
GlaxoSmithKline has announced encouraging phase II results for its mRNA seasonal influenza vaccine, showing strong immune responses against influenza A and B strains in adults. These findings confirm the vaccine’s safety and efficacy, paving the way for phase III clinical trials. The company is also expanding its vaccine development efforts through a new licensing agreement with CureVac and investments in mRNA technology.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
